With 2.57 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.63 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.535 whereas the lowest price it dropped to was $0.35. The 52-week range on ENVB shows that it touched its highest point at $2.92 and its lowest point at $0.30 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ENVB was up-trending over the past week, with a rise of 54.69%, but this was up by 50.40% over a month. Three-month performance surged to 18.80% while six-month performance rose 11.31%. The stock lost -60.24% in the past year, while it has gained 40.88% so far this year.
Float and Shares Shorts:
At present, 10.17 million ENVB shares are outstanding with a float of 9.30 million shares on hand for trading. On 2024-10-31, short shares totaled 0.33 million, which was 370.0 higher than short shares on 1727654400. In addition to Dr. Joseph Edward Tucker Ph.D. as the firm’s CEO & Director, Mr. Kevin M. Coveney CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.07059 of ENVB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, ENVB reported revenue of $0.0 and operating income of -$2083192.0. Over the past year, revenue came in at $0.00 while operating income stood at -$64.62M. The EBITDA in the recently reported quarter was -$1997755.0 and diluted EPS was -$0.24.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$2.08 being high and -$2.08 being low. For ENVB, this leads to a yearly average estimate of -$2.08.
